57
Participants
Start Date
December 13, 2018
Primary Completion Date
March 30, 2022
Study Completion Date
March 30, 2022
Cavrotolimod
Intratumorally dosed cavrotolimod.
Pembrolizumab
Pembrolizumab dosing as per the US prescribing information.
Cemiplimab
Cemiplimab dosing as per the US prescribing information.
Cavrotolimod
Subcutaneously dosed cavrotolimod
Perlmutter Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Medical Center / Hillman Cancer Center, Pittsburgh
West Virginia Cancer Institute, Morgantown
Duke Cancer Institute, Durham
Sylvester Comprehensive Cancer Center, Miami
Norton Cancer Center, Louisville
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati, Cincinnati
Holden Comprehensive Cancer Center, Iowa City
Northwestern University Feinberg School of Medicine, Chicago
Washington University St. Louis, St Louis
Sammons Cancer Center, Dallas
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Western States Cancer Center, Englewood
University of Arizona Cancer Center, Tucson
John Wayne Cancer Institute / Providence St. John's Health Center, Santa Monica
University of California Irvine, Orange
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Oregon Health and Science University, Portland
University of Washington- Seattle Cancer Care Alliance, Seattle
Dana Farber Cancer Institute, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Valley - Mount Sinai Comprehensive Cancer Center, Paramus
Lead Sponsor
Exicure, Inc.
INDUSTRY